Novo Nordisk Announces $4.1 Billion Investment in North Carolina for Wegovy and Ozempic Production Boost

By Madz Dizon

Jun 25, 2024 12:50 AM EDT

Novo Nordisk Announces $4.1 Billion Investment in North Carolina for Wegovy and Ozempic Production Boost
The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017, the day before they release their yearly financial results.
(Photo : LISELOTTE SABROE/Ritzau Scanpix/AFP via Getty Images)

Novo Nordisk revealed its intention on Monday to construct a $4.1 billion facility in North Carolina, responding to the growing demand for its highly sought-after weight-loss medications in recent months.

Novo Nordisk Plans Massive Expansion

This new facility in Clayton, NC will be the Danish company's second fill as well as finishing manufacturing plant in the area, adding to their existing presence with a total of four facilities.

According to The Hill, Novo Nordisk, a pharmaceutical company renowned for its weight-loss and diabetes drugs Wegovy and Ozempic, has announced plans to construct a new facility. 

This expansive facility will cover 56 acres and provide an additional 1.4 million square feet of production space. It will effectively double the combined square footage of the company's three existing facilities in North Carolina.

Novo Nordisk announced that the life science investment is the largest in the state's history. The company announced plans to create 1,000 additional jobs, which will supplement the existing 2,500 positions in the region.

READ NEXT: California Democrats Delay Minimum Wage Hike for Healthcare Workers Amid Budget Crisis

Novo Nordisk Announces $70K Average Salary for New Jobs in NC Expansion

According to Christopher Chung, the chief executive officer of the Economic Development Partnership of North Carolina, this announcement is set to be the biggest life sciences investment in the history of the state. 

The partnership announced in a news release that the average salary for the newly created positions will be $70,000, surpassing Johnston County's average of $50,605, AP reported.

The company announced that the future production site will be finished in phases between 2027 and 2029. It will have the capability to produce multiple treatments. 

Novo Nordisk is widely recognized for its production of insulin, which is used to treat diabetes.

READ MORE: IRS: Majority of Employee Retention Credit Claims at Risk of Being Improper

© 2024 VCPOST, All rights reserved. Do not reproduce without permission.

Join the Conversation

Real Time Analytics